

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Benjamin Oshlack et al.

Application No.: 10/731,678

Confirmation No.: 4265

Filed: December 8, 2003

Art Unit: 1615

For: ORALLY ADMINSTRABLE OPIOID
FORMULATIONS HAVING EXTENDED
DURATION OF EFFECT

Examiner: M. Fitzgerald

AMENDMENT AFTER FINAL ACTION UNDER 37 C.F.R. 1.116

MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action mailed on October 20, 2006 and in accordance with Rule 116 of the Rules of Practice, please enter the following amendments and consider the accompanying Remarks. The following documents are also submitted concurrently herewith and in support of this Response: (1) a Petition for Extension of Time, requesting that the time period for response be extended for a period of **three (3)** months, from **January 20, 2007** up to and including **April 20, 2007**; (2) a Notice of Appeal; (3) a Terminal Disclaimer pursuant to 37 C.F.R. § 1.321(c); and (4) a Petition to Amend Inventorship of this application, including (a) a statement by Frank Pedi, Jr., the person being added as a co-inventor, (b) a Declaration and Power of Attorney signed by each of the inventors Benjamin Oshlack, Mark Chasin and Frank Pedi, Jr., and (c) the written statement of Philip C. Strassburger, an authorized officer for Purdue Pharma, L.P. (the assignee of this application), consenting to the change of inventorship.

A Fee Transmittal Form is also submitted herewith, along with payment of the estimated Extension, Appeal, Terminal Disclaimer, and Processing Fees required for these submissions. It is believed that no additional fees are required. However, should the U.S. Patent and Trademark Office determine that any additional fee is required (including any deficiency in the above-mentioned fees) or that any refund is owed for this application, then Applicants hereby authorize and request that the Commissioner charge the required fee(s) and/or credit the refund(s) owed to Deposit Account No. 04-0100 of Applicants' undersigned attorneys/agents.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 7 of this paper.

* * * * *